The effect of infliximab on circulating levels of leptin, adiponectin and resistin in patients with inflammatory bowel disease

Eur J Gastroenterol Hepatol. 2007 Sep;19(9):789-94. doi: 10.1097/MEG.0b013e3282202bca.


Background: Tumour necrosis factor alpha is a critical mediator of inflammation-related altered metabolism in inflammatory bowel disease (IBD), possibly through its interaction with adipokines, which play an important role in IBD. Infliximab is a well established antitumour necrosis factor alpha treatment in IBD.

Aim and methods: We studied serum levels of leptin, adiponectin and resistin in 20 IBD patients before and after infliximab treatment using commercially available enzyme-linked immunosorbent assays. The results were correlated with alterations of disease activity, BMI and C-reactive protein.

Results: Infliximab induced clinical response or remission in 18 out of 20 treated IBD patients. Mean serum-leptin levels were 4.6+/-0.5 and 5.1+/-0.5 ng/ml (P=0.41), mean serum-adiponectin levels were 10513.9+/-1216.9 and 9653.5+/-1031.5 ng/ml (P=0.36) and mean serum-resistin levels were 26.3+/-4.1 and 13.9+/-1.4 ng/ml (P=0.004), before and after infliximab treatment, respectively. No significant correlation between the changes of BMI, C-reactive protein or the clinical indices of activity and alterations of the examined adipokines was found.

Conclusions: Serum levels of leptin and adiponectin had no significant alterations, whereas serum-resistin levels are significantly decreased after infliximab therapy in IBD patients, suggesting a possible proinflammatory status for resistin in IBD and a role as a marker of successful therapy.

MeSH terms

  • Adiponectin / blood
  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Biomarkers / blood
  • Body Mass Index
  • C-Reactive Protein / metabolism
  • Female
  • Gastrointestinal Agents / therapeutic use*
  • Humans
  • Inflammatory Bowel Diseases / blood
  • Inflammatory Bowel Diseases / drug therapy*
  • Infliximab
  • Leptin / blood
  • Male
  • Middle Aged
  • Peptide Hormones / blood*
  • Prospective Studies
  • Resistin / blood
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors


  • Adiponectin
  • Antibodies, Monoclonal
  • Biomarkers
  • Gastrointestinal Agents
  • Leptin
  • Peptide Hormones
  • Resistin
  • Tumor Necrosis Factor-alpha
  • C-Reactive Protein
  • Infliximab